Table 1.
Participant characteristics of study subjects
| Median (IQR) or number (%) | Range | |
|---|---|---|
| Age, years | 28.5 (24.4–36.0) | 18.7–72.8 |
| Sex, female | 68 (54.4%) | |
| Skin autofluorescence, AU (N = 121) | 1.8 (1.6–2.1) | 1.2–3.4 |
| FMD, % | 9.7 (6.0-11.9) | 2.3–18.4 |
| Allometrically scaled FMD, % | 8.0 (6.9–9.2) | 5.6–12.4 |
| Baseline diameter, mm | 3.6 (3.1–4.1) | 2.4-5.0 |
| Peak diameter, mm | 4.0 (3.4–4.4) | 2.7–5.4 |
| Absolute FMD change, mm | 0.3 (0.2–0.4) | 0.1–0.7 |
| Shear rate, sec−1 | 1415.1 (1039.4-1743.7) | 712.7-2545.5 |
| BMI, kg/m2 | 22.9 (20.3–25.7) | 16.1–38.2 |
| Waist circumference, cm | 80.0 (72.5–90.0) | 57.8–127.0 |
| Fat-free mass, % | 72.7 (68.9–80.0) | 51.8–94.1 |
| Fat mass, % | 27.3 (20.0-31.1) | 5.9–48.2 |
| Total body water, % | 53.3 (50.0-58.3) | 38.2–67.3 |
| Skeletal muscle mass, % (N = 102) | 34.9 (31.2–38.3) | 20.6–45.4 |
| Visceral adipose tissue, % | 2.2 (1.5–2.9) | 0.1–7.1 |
| Physical activity, MET minutes/week | 2399 (1138–4320) | 0-10479 |
| Systolic blood pressure, mmHg | 108.3 (101.7–116.0) | 90.3-155.3 |
| Diastolic blood pressure, mmHg | 68.7 (64.0–73.0) | 56.3–90.7 |
| Mean arterial pressure, mmHg | 81.6 (76.4–87.7) | 67.7-108.7 |
| Heart rate, beats/min | 60.0 (52.3–67.3) | 37.0-90.7 |
| Glucose, mmol/L (N = 117) | 5.3 (5.0-5.5) | 4.4–6.8 |
| Insulin, pmol/ml (N = 117) | 32.5 (21.3–44.0) | 5.1-170.4 |
| sRAGE, pg/mL (N = 117) | 1832 (1296–2384) | 363–4731 |
| Total Cholesterol, mmol/L (N = 117) | 5.0 (4.4–5.9) | 3.0-22.2 |
| LDL Cholesterol, mmol/L (N = 117) | 3.2 (2.5-4.0) | 1.4–20.2 |
| HDL Cholesterol, mmol/L (N = 117) | 1.7 (1.5-2.0) | 0.9–3.2 |
| Triglycerides, mmol/L (N = 117) | 0.8 (0.7–1.2) | 0.3–3.5 |
| hsCRP, mg/l (N = 117) | 0.6 (0.3–1.4) | 0.0-10.7 |
| HbA1c, % (N = 117) | 5.1 (5.0-5.3) | 4.4–6.6 |
| HOMA-IR, (N = 117) | 1.3 (0.9–1.8) | 0.2–7.4 |
N = 125 unless otherwise stated. Values are shown as median (IQR) or number (percentage). Abbreviations: AU, arbitrary units; BMI, body mass index; FMD, flow-mediated dilation; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDL, low-density lipoprotein; MET, metabolic equivalent task; sRAGE, soluble receptor for advanced glycation end-products